| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb0d5481ad019c6300fe430e580aaeef |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2230-201
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F40-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-1723 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F40-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-1459
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H40-67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-14532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-1473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-7275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H15-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
| filingDate |
2020-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f20011418f17c6dbdceeddb0814d9cd2 |
| publicationDate |
2022-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4076156-A1 |
| titleOfInvention |
Therapeutic zone assessor |
| abstract |
Systems and methods are provided for identifying therapeutic zones where there is glycemic dysfunction of a specific type that can be addressed by making strategic changes to behavior and/or therapy parameters. Systems and methods described herein evaluate large historical data sets to: identify a therapeutic zone or zones with glycemic dysfunction that are most readily addressable; quantify the glycemic impact of a plurality of different therapeutic adjustments in terms of either adjustments to historical doses or the parameters of a prospective dosing strategy to determine the highest possible improvement; and/or identify patient dosing strategies to provide therapy recommendations adapted for the patient's preferred behavioral dosing strategy. |
| priorityDate |
2019-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |